RAC1, a Potential Diagnostic and Prognostic Marker for Diffuse Large B Cell Lymphoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Diffuse large B cell lymphoma (DLBCL) diagnosis and prognosis require further understanding of underlying genetic alterations.
• The role of RAC1, a gene involved in B cell receptor signaling, in DLBCL pathogenesis remains underexplored.

Purpose of the Study:

• To investigate the association between RAC1 gene expression and the clinical features, survival, and risk of diffuse large B cell lymphoma (DLBCL).

Main Methods:

• Bioinformatic and molecular analyses using The Cancer Genome Atlas (TCGA) data.
• Statistical methods including Wilcoxon signed-rank test, logistic regression, Kaplan-Meier, and Cox regression analyses.
• Development of a nomogram to predict DLBCL risk based on RAC1 expression.

Main Results:

• RAC1 expression is significantly higher in DLBCL tissues compared to normal tissues and lymphadenitis.
• Elevated RAC1 levels correlate with advanced clinical stage and serve as an independent prognostic factor for overall survival in DLBCL patients.
• RAC1 expression shows a negative correlation with Bruton's tyrosine kinase (BTK).

Conclusions:

• RAC1 expression patterns are significantly associated with the clinical characteristics and overall survival of DLBCL patients.
• RAC1 may serve as a potential biomarker for predicting the development and prognosis of diffuse large B cell lymphoma.
• Further research into RAC1's role could offer new diagnostic and therapeutic strategies for DLBCL.